Vor Biopharma (VOR) Price & Analysis

Q: What was Vor Biopharma’s price range in the past 12 months?

Vor Biopharma lowest stock price was $0.13 and its highest was $3.29 in the past 12 months.

Q: What is Vor Biopharma’s market cap?

Vor Biopharma’s market cap is $202.69M.

Q: When is Vor Biopharma’s upcoming earnings report date?

Vor Biopharma’s upcoming earnings report date is Mar 19, 2026 which is in 182 days.

Q: How were Vor Biopharma’s earnings last quarter?

Vor Biopharma released its earnings results on Aug 07, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.438 by $0.178.

Q: Is Vor Biopharma overvalued?

According to Wall Street analysts Vor Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Vor Biopharma pay dividends?

Vor Biopharma does not currently pay dividends.

Q: What is Vor Biopharma’s EPS estimate?

Vor Biopharma’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Vor Biopharma have?

Vor Biopharma has 126,683,110 shares outstanding.

Q: What happened to Vor Biopharma’s price movement after its last earnings report?

Vor Biopharma reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.438. Following the earnings report the stock price went down -0.957%.

Q: Which hedge fund is a major shareholder of Vor Biopharma?

Currently, no hedge funds are holding shares in VOR

Compare

918 Followers

VOR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.13 - $3.29

Previous CloseN/A

Volume424.02K

Average Volume (3M)4.90M

Market Cap

$202.69M

Enterprise Value-$38.26K

Total Cash (Recent Filing)$200.56M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta4.29

Next Earnings

Mar 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding126,683,110

10 Day Avg. Volume4,964,291

30 Day Avg. Volume4,901,123

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap>-0.01

Enterprise Value/Revenue-0.01

Enterprise Value/Gross Profit0.04

Enterprise Value/Ebitda<0.01

Forecast

1Y Price Target

$1.18

Price Target Upside-24.84% Downside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase 3 clinical study for telitacicept in primary Sjögren's disease in China achieved the primary endpoint, showing improved disease activity and a favorable safety profile.

Financial StabilityThe company reported cash, cash equivalents, and marketable securities of approximately $200.6M, which is believed to be sufficient to fund operations into 1Q27.

Strategic ExpansionVor announced an exclusive license agreement with RemeGen Co., Ltd to develop and commercialize telitacicept in ex-Greater China geographies.

Bears Say

Financial PerformanceVor Bio reported a net loss of $12.56 per share for 2Q25, compared to the consensus estimated net loss of $2.92 per share.

Vor Biopharma News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: -1X SHORT VIX FUTURES...

13d ago

BHP

MPW

Vor Bio appoints Osovsky as General Counsel

Vor Bio (VOR) announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years...

16d ago

VOR

ITOS

Vor Bio’s telitacicept achieved primary endpoint in Phase 3 study

Vor Bio (VOR) announced that its collaborator, RemeGen (REGMF), achieved the primary endpoint in Stage A of a...

22d ago

VOR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: TORM plc (TRMD) 21.83%...

28d ago

JHX

VOR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Gorilla Technology Group Inc...

29d ago

SLS

VOR

Vor Biopharma Announces 1-for-20 Reverse Stock Split

The latest update is out from Vor Biopharma ( ($VOR) ). On September 17, 2025, Vor Biopharma Inc....

1d ago

VOR

Vor Biopharma Focuses on Telitacicept Development Strategy

An announcement from Vor Biopharma ( ($VOR) ) is now available. Vor Biopharma Inc. has announced its strategic...

16d ago

VOR

Vor Biopharma Appoints Sarah Reed to Board

Vor Biopharma ( ($VOR) ) has issued an update. Vor Biopharma recently experienced significant changes in its Board...

22d ago

VOR

Vor Biopharma Files Prospectus for $119.7M Stock Sale

Vor Biopharma ( ($VOR) ) has shared an update. Vor Biopharma Inc. held a special meeting on August...

22d ago

VOR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Upexi (UPXI) 475.77% +32.39,...

1M ago

ABR

IEP

Positive Phase 3 Results and Strong Financial Position Support Buy Rating for Vor Biopharma

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Vor Biopharma and keeping the price target...

1M ago

VOR

Vor Biopharma options imply 7.4% move in share price post-earnings

Pre-earnings options volume in Vor Bio (VOR)pharma is 1.5x normal with puts leading calls 7:5. Implied volatility suggests...

1M ago

VOR

Vor Bio, RemeGen announce Phase 3 study of telitacicept met primary endpoint

Vor Bio (VOR) announced that its collaborator, RemeGen (REGMF), achieved the primary endpoint in a Phase 3 clinical...

1M ago

VOR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Vor Biopharma (VOR) 132.73%...

1M ago

VOR

YOU

VOR FAQ

What was Vor Biopharma’s price range in the past 12 months?

Vor Biopharma lowest stock price was $0.13 and its highest was $3.29 in the past 12 months.

What is Vor Biopharma’s market cap?

Vor Biopharma’s market cap is $202.69M.

When is Vor Biopharma’s upcoming earnings report date?

Vor Biopharma’s upcoming earnings report date is Mar 19, 2026 which is in 182 days.

How were Vor Biopharma’s earnings last quarter?

Vor Biopharma released its earnings results on Aug 07, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.438 by $0.178.

Is Vor Biopharma overvalued?

According to Wall Street analysts Vor Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vor Biopharma pay dividends?

Vor Biopharma does not currently pay dividends.

What is Vor Biopharma’s EPS estimate?

Vor Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Vor Biopharma have?

Vor Biopharma has 126,683,110 shares outstanding.

What happened to Vor Biopharma’s price movement after its last earnings report?

Vor Biopharma reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.438. Following the earnings report the stock price went down -0.957%.

Which hedge fund is a major shareholder of Vor Biopharma?

Currently, no hedge funds are holding shares in VOR

Vor Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-125.43%

Trailing 12-Months

Asset Growth

45.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vor Biopharma

Vor Biopharma (VOR) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat cancer. The company is pioneering the development of engineered hematopoietic stem cells (eHSCs) to enable targeted cancer therapies while reducing off-target toxicity. Vor Biopharma aims to transform the treatment landscape for patients with hematologic malignancies by utilizing its proprietary technology to enhance the therapeutic index of anticancer agents.

Vor Biopharma (VOR) Earnings & Revenues

Historic Earnings Reports

VOR Stock 12 Month Forecast

Average Price Target

$1.18

▼(-24.84% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.1692307692307695,2.2384615384615385,2.307692307692308,2.376923076923077,2.4461538461538463,2.5153846153846153,2.5846153846153848,2.6538461538461537,2.723076923076923,2.792307692307692,2.8615384615384616,2.930769230769231,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.0292307692307694,1.9584615384615385,1.8876923076923078,1.8169230769230769,1.7461538461538462,1.6753846153846155,1.6046153846153848,1.5338461538461539,1.463076923076923,1.3923076923076922,1.3215384615384616,1.2507692307692309,{"y":1.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,1.9615384615384617,1.8230769230769233,1.6846153846153846,1.5461538461538462,1.4076923076923078,1.2692307692307692,1.1307692307692307,0.9923076923076923,0.8538461538461539,0.7153846153846155,0.5769230769230769,0.43846153846153846,{"y":0.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >